2018 American Transplant Congress
CFZ533, a New Anti-CD40 mAB Demonstrates Comparable Efficacy and Better Renal Function versus Tacrolimus in De-Novo CNI-Free Kidney Transplantation
1CFZ533 Study Group, Basel, Switzerland; 2Novartis Pharma, Basel, Switzerland.
Purpose: To assess the potential of CFZ533 as primary immunosuppressant in a calcineurin(CNI)-free regimen in de novo kidney transplant (KTx) patients(pts).Method: CFZ533 is a new,…2018 American Transplant Congress
Donor-Specific Antibody Mediates Chronic, but Not Acute, Kidney Allograft Rejection in the Absence of Natural Killer Cells
Immunology and Glickman Urological Institute, Cleveland Clinic, Cleveland, OH.
The incidence of antibody-mediated kidney graft rejection continues to increase. We previously reported that dysregulated donor-specific antibody (DSA) responses were induced in B6.CCR5-/- mice transplanted…2018 American Transplant Congress
Impact of Rapid Discontinuation of Prednisone on Kidney Transplant Outcomes in At-Risk Subpopulations: An OPTN/SRTR Analysis
1Public Health, U of MN, Mpls, MN; 2Surgery, U of MN, Mpls, MN.
Objective: Successful RDP (rapid discontinuation of prednisone <1 week post-tx) after kidney transplant (KTx) has been reported for low-risk populations. We studied the impact of…2018 American Transplant Congress
Early Considerations for Deceased Donor Chains
Background: The potential use of deceased kidney donors (DDs) to initiate kidney paired donation (KPD) chains (DD chains) has been of interest to the transplant…2018 American Transplant Congress
Comparison of Recipients with Early and Late Presenting Polyomavirus Nephropathy (PVN) with Regard to Histological Findings and Graft Survival: What is the Influence of CD4/CD8 Ratio on the Presenting Time of PVN
Introduction: PVN is a common complication occurring around 12 mo after renal transplant (RT). We aimed to explore the differences between early and late-onset PVN…2018 American Transplant Congress
Pancreas Transplant Recipients with End-Stage Renal Disease Benefit from Kidney Transplantation
Background: End-stage renal disease (ESRD) has been shown after pancreas transplant alone (PTA), however, the benefit of kidney transplantation (KT) in PTA recipients with ESRD…2018 American Transplant Congress
Shared HLA Specificities between the Blood and Transplant Donor Increases the Risk of De Novo DSA Development Following Blood Transfusion in Transplant Recipients
Introduction: Blood transfusions post-transplant have been shown to be associated with the development of de novo DSA and inferior allograft outcomes. The mechanisms behind this…2018 American Transplant Congress
HLA Eplet Mismatch and Donor Specific Antibodies in Kidney Transplantation
BACKGROUND: Although HLA matching improves graft survival in kidney transplant recipients (KTx), eplet mismatches provide higher resolution information, and could better predict the development of…2018 American Transplant Congress
Emergence of a Costimulation-Susceptible T Cell Repertoire Post-Alemtuzumab Induction
Kidney transplant patients treated with belatacept-based regimens without depletional induction have higher rates of costimulation blockade resistant rejection (CoBRR). In contrast, belatacept effectively prevents rejection…2018 American Transplant Congress
Improving Prognostication amongst Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma: An International, 16-Center Study to Validate and Recalibrate HALTHCC
Objective: Prognosticating outcomes in liver transplant (LT) for hepatocellular carcinoma (HCC) continues to challenge the field. Whereas adoption of the binary Milan Criteria (MC) generalized…
- « Previous Page
- 1
- …
- 193
- 194
- 195
- 196
- 197
- …
- 211
- Next Page »